Anti–IL-4Ra therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis

Anti–IL-4Ra therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis

Background: Allergic bronchopulmonary aspergillosis (ABPA) is a disease resulting from an overactive type 2 response to Aspergillus. Initial studies suggest that asthma biologics can effectively treat ABPA, but it is unclear which biologic class is superior. Objective: We sought to compare the effec...

Full description

Bibliographic Details
Main Authors: Pedro A. Lamothe, MD, PhD, Charles Lewis Humphrey Pruett, MS, Natalia Smirnova, MD, Aaron Shepherd, MD, Martin C. Runnstrom, MD, Jiwon Park, BA, Rebecca H. Zhang, MS, Leshan Zhao, MS, Colin Swenson, MD, F. Eun-Hyung Lee, MD
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
ABPA
allergic bronchopulmonary aspergillosis
asthma biologics
dupilumab
severe asthma
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829324001656

Internet

http://www.sciencedirect.com/science/article/pii/S2772829324001656

Similar Items